Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - Additional Information (Details)

v3.19.3
Licensing and Other Arrangements - Novartis - Additional Information (Details)
$ / shares in Units, € in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 24, 2017
USD ($)
Agreement
Obligation
$ / shares
shares
Aug. 24, 2017
EUR (€)
Agreement
Obligation
shares
Sep. 30, 2015
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2018
USD ($)
Novartis Pharma AG [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront payment received $ 25,700,000                  
Common stock aggregate fair value 4,800,000                  
Common stock premium $ 200,000                  
Number of license agreements | Agreement 2 2                
Number of performance obligations | Obligation 2 2                
Remaining performance obligations $ 0                  
License agreement transaction price 40,200,000                  
Contract liabilities       $ 0   $ 0       $ 0
Contract assets       0   0       0
Revenue recognize       0 $ 0 0 $ 0      
Capitalized contract costs       0   0       0
Novartis Pharma AG [Member] | Licenses and Related Materials, Process and Know-How and Filings to Regulatory Authority [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Recognized the entire transaction price as revenue upon completion of delivery               $ 40,200,000    
Novartis Pharma AG [Member] | Common Stock [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Cash received from sale of shares $ 5,000,000                  
Number of shares sold | shares 539,131 539,131                
Sale of stock price per share | $ / shares $ 9.2742                  
Common stock closing price | $ / shares $ 8.93                  
Novartis Pharma AG [Member] | Les Laboratories Servier [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Repayments of debt $ 14,300,000 € 12.0                
Novartis Pharma AG [Member] | XOMA-052 License Agreement [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
License agreement consideration received 30,000,000                  
Upfront payment received 15,700,000                  
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000,000                  
Agreement termination prior written notice period 6 months 6 months                
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront payment received $ 10,000,000                  
Novartis International [Member] | License Agreement [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones           470,000,000        
Contract liabilities       0   0       0
Contract assets       0   0       0
Capitalized contract costs       $ 0   $ 0       $ 0
Agreement termination notice period     180 days              
Upfront payment recognized as revenue                 $ 37,000,000  
Milestone received under the collaboration agreement               $ 10,000,000